Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.

Clin Cancer Res. 1999 Sep;5(9):2464-9. Unique Identifier : AIDSLINE MED/99427966
Shibakita M; Tachibana M; Dhar DK; Kotoh T; Kinugasa S; Kubota H; Masunaga R; Nagasue N; Second Department of Surgery, Shimane Medical University, Izumo,; Japan. nigeka88@shimane-med.ac.jp

Abstract: Esophageal carcinomas have recently been shown to express Fas ligand (FasL) and down-regulate Fas to escape from host immune surveillance. However, the prognostic importance of Fas/FasL and their correlation with clinicopathological characteristics are yet to be delineated in this highly malignant carcinoma. Specimens from 106 esophageal squamous cell carcinoma patients were used for immunohistochemical evaluation of Fas, FasL, and CD8 expressions. Fifty-two (49%) and 34 (32%) patients were positive for FasL and Fas, respectively. There were no associations between FasL expression and clinicopathological characteristics except lymph vessel invasion. Strong FasL expression correlated with significant (P = 0.0011) decrease in tumor nest CD8+ cells. However, neither FasL nor CD8+ had any impact on patient survival. Strong Fas expression was correlated with depth of invasion (40.3% in pT1,T2 versus 20.5% in pT3,T4; P = 0.0308), histological differentiation (45.7% in well versus 25.4% in nonwell; P = 0.0347), and lymph node metastasis (22.6% in positive versus 45.5% in negative; P = 0.0129). Fas expression was one of the independent favorable prognosticators for patients' survival (risk ratio, 3.26; P = 0.0103) in esophageal SCC. Fas expression was an independent prognosticator for recurrence-free survival, whereas FasL expression did not influence the survival in esophageal squamous cell carcinoma. Down-regulation of tumor Fas may be the hallmark of immune privilege for the tumor, thus causing the patients' poorer outcome. Tumor FasL may counterattack the host immune cells to such an extent that the prognosis is not affected.

Keywords: JOURNAL ARTICLE Adult Aged Aged, 80 and over Antigens, CD8/BIOSYNTHESIS Antigens, CD95/*BIOSYNTHESIS Carcinoma, Squamous Cell/*METABOLISM/PATHOLOGY/SURGERY CD8-Positive T-Lymphocytes/CYTOLOGY Esophageal Neoplasms/*METABOLISM/PATHOLOGY/SURGERY Female Human Immunohistochemistry Lymphocyte Count Male Membrane Glycoproteins/*BIOSYNTHESIS Middle Age Multivariate Analysis Neoplasm Recurrence, Local/METABOLISM Prognosis Survival Analysis

000130
A0010902

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .